LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia
NCT: NCT07312214 · RECRUITING
Brief Summary
The goal of this clinical trial is to learn if LED repeated low-level red light (RLRL) therapy works to treat pathologic myopia in adults. It will also learn about the safety of LED-RLRL. The main questions it aims to answer are: Does LED-RLRL modulate choroidal microcirculation to retard retinal atrophy in pathological myopia? What medical problems do participants have when receiving LED-RLRL therapy? Researchers will compare with a sham device (identical in appearance but delivering \<10% of the original device's energy output) to see if LED-RLRL works to treat pathologic myopia. Participants will: Take LED-RLRL or sham LED-RLRL twice daily, 3 minutes per session, 5 days per week, for a total duration of 12 months. Visit the clinic once every 3 months for checkups and tests. Keep a diary of their symptoms and their visual perception.
Frequently Asked Questions
What is LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia?
LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia is a clinical trial registered under NCT07312214. Current status: RECRUITING.
What is the status of NCT07312214?
The current status of NCT07312214 (LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia) is: RECRUITING.
When did LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia start?
LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia started on 2025-12-31.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.